{"title":"中和单克隆抗体在现实生活中治疗COVID-19的适应症:与对照随机试验的巨大差距","authors":"M. Hildebrand, J. Goffard","doi":"10.30637/2022.22-043","DOIUrl":null,"url":null,"abstract":"Anti-SARS-CoV-2 neutralizing monoclonal antibodies treatments have been studied through randomized controlled trials and have demonstrated efficacy for prevention and early COVID-19 treatment. Their use in real life is different from studies in many points. Variant changes, vaccination coverage, treated groups with nAbs which are different from clinical trials are topics discussed in this paper.","PeriodicalId":39361,"journal":{"name":"Revue Medicale de Bruxelles","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Indication for neutralizing monoclonal antibodies for treatment of COVID-19 in real life: the big gap with controlled randomized trials\",\"authors\":\"M. Hildebrand, J. Goffard\",\"doi\":\"10.30637/2022.22-043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Anti-SARS-CoV-2 neutralizing monoclonal antibodies treatments have been studied through randomized controlled trials and have demonstrated efficacy for prevention and early COVID-19 treatment. Their use in real life is different from studies in many points. Variant changes, vaccination coverage, treated groups with nAbs which are different from clinical trials are topics discussed in this paper.\",\"PeriodicalId\":39361,\"journal\":{\"name\":\"Revue Medicale de Bruxelles\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue Medicale de Bruxelles\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30637/2022.22-043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue Medicale de Bruxelles","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30637/2022.22-043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Indication for neutralizing monoclonal antibodies for treatment of COVID-19 in real life: the big gap with controlled randomized trials
Anti-SARS-CoV-2 neutralizing monoclonal antibodies treatments have been studied through randomized controlled trials and have demonstrated efficacy for prevention and early COVID-19 treatment. Their use in real life is different from studies in many points. Variant changes, vaccination coverage, treated groups with nAbs which are different from clinical trials are topics discussed in this paper.
期刊介绍:
Des articles originaux et de synthèse, des cas cliniques et anatomopathologiques, des actualités thérapeutiques, des comptes rendus de symposia, des imageries, une rubrique consacrée à l"histoire de la médecine, des annonces de prix, ainsi que le programme de réunions scientifiques et sociales, des nominations récentes, des propositions d"emploi, etc.